CO6270206A2 - SOLID DISPERSION PRODUCT OF DRUGS BASED ON N-ARIL UREA - Google Patents
SOLID DISPERSION PRODUCT OF DRUGS BASED ON N-ARIL UREAInfo
- Publication number
- CO6270206A2 CO6270206A2 CO10049271A CO10049271A CO6270206A2 CO 6270206 A2 CO6270206 A2 CO 6270206A2 CO 10049271 A CO10049271 A CO 10049271A CO 10049271 A CO10049271 A CO 10049271A CO 6270206 A2 CO6270206 A2 CO 6270206A2
- Authority
- CO
- Colombia
- Prior art keywords
- solid dispersion
- dispersion product
- pharmaceutically acceptable
- agent
- matrix forming
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un producto de dispersion solida que comprende al menos un agente con actividad farmacéutica, que se obtiene a) preparando una mezcla liquida que contiene el al menos un agente activo, al menos un agente formador de matriz farmacéuticamente aceptable, al menos un agente tensioactivo farmacéuticamente aceptable y al menos un solvente, y b) eliminando el o los solventes de la mezcla liquida para obtener el producto de dispersion solida.2.- El producto de dispersion solida de la reivindicacion 1, donde se agrega al menos un relleno a la mezcla liquida antes de eliminar el o los solventes. 3.- El producto de dispersion solida de la reivindicacion 1, donde la relacion de masa entre el agente activo y el agente formador de matriz farmacéuticamente aceptable es de entre 0,01:1 y 1:3. 4.- El producto de dispersion solida de la reivindicacion 1, donde la relacion de masa entre el agente activo y el agente tensioactivo farmacéuticamente aceptable es de entre 0,1:1 y 1:7. 5.- El producto de dispersion solida de la reivindicacion 1, donde el agente formador de matriz farmacéuticarnente aceptable se selecciona del grupo que consiste en ciclodextrinas, polimeros farmacéuticamente aceptables, lipidos o combinaciones de dos o mas de los anteriores. 6.- El producto de dispersion solida de la reivindicacion 1, donde dicho agente formador de matriz farmacéuticamente aceptable se selecciona del grupo que consiste en ésteres de celulosa, éteres de celulosa, rnaltodextrinas, homopolimeros de N-vinil pirrolidona, copolimeros de N-vinil pirrolidona y combinaciones de dos o mas de los anteriores. 7.- El producto de dispersion solida de la reivindicacion 1, donde dicho agente formador de matriz farmacéuticamente aceptable se selecciona del grupo que consiste en poli N-vinilpirrolidonas, copolimeros de N-vinil pirrolidona y acetato de vinilo y combinaciones de los anteriores.1. A solid dispersion product comprising at least one agent with pharmaceutical activity, which is obtained a) preparing a liquid mixture containing the at least one active agent, at least one pharmaceutically acceptable matrix forming agent, at least one agent pharmaceutically acceptable surfactant and at least one solvent, and b) removing the solvent (s) from the liquid mixture to obtain the solid dispersion product. 2. The solid dispersion product of claim 1, wherein at least one filler is added to the liquid mixture before removing the solvent (s). 3. The solid dispersion product of claim 1, wherein the mass ratio between the active agent and the pharmaceutically acceptable matrix forming agent is between 0.01: 1 and 1: 3. 4. The solid dispersion product of claim 1, wherein the mass ratio between the active agent and the pharmaceutically acceptable surfactant is between 0.1: 1 and 1: 7. 5. The solid dispersion product of claim 1, wherein the pharmaceutically acceptable matrix forming agent is selected from the group consisting of cyclodextrins, pharmaceutically acceptable polymers, lipids or combinations of two or more of the foregoing. 6. The solid dispersion product of claim 1, wherein said pharmaceutically acceptable matrix forming agent is selected from the group consisting of cellulose esters, cellulose ethers, rnaltodextrins, N-vinyl pyrrolidone homopolymers, N-vinyl copolymers pyrrolidone and combinations of two or more of the above. 7. The solid dispersion product of claim 1, wherein said pharmaceutically acceptable matrix forming agent is selected from the group consisting of poly N-vinyl pyrrolidones, copolymers of N-vinyl pyrrolidone and vinyl acetate and combinations of the foregoing.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99961807P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270206A2 true CO6270206A2 (en) | 2011-04-20 |
Family
ID=40089463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10049271A CO6270206A2 (en) | 2007-10-19 | 2010-04-27 | SOLID DISPERSION PRODUCT OF DRUGS BASED ON N-ARIL UREA |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2197425A2 (en) |
| JP (1) | JP2011500649A (en) |
| KR (1) | KR20100087170A (en) |
| CN (1) | CN101827584A (en) |
| AU (1) | AU2008313622A1 (en) |
| BR (1) | BRPI0818340A2 (en) |
| CA (1) | CA2699301A1 (en) |
| CO (1) | CO6270206A2 (en) |
| CR (1) | CR11442A (en) |
| DO (1) | DOP2010000117A (en) |
| EC (1) | ECSP10010183A (en) |
| GT (1) | GT201000102A (en) |
| MX (1) | MX2010004291A (en) |
| PA (1) | PA8800101A1 (en) |
| RU (1) | RU2010119929A (en) |
| UA (1) | UA100865C2 (en) |
| WO (1) | WO2009050291A2 (en) |
| ZA (1) | ZA201002095B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| JO3002B1 (en) | 2009-08-28 | 2016-09-05 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| TW201202234A (en) * | 2010-06-09 | 2012-01-16 | Abbott Lab | Solid dispersions containing kinase inhibitors |
| MX354725B (en) | 2011-11-11 | 2018-03-16 | Novartis Ag | Method of treating a proliferative disease. |
| JP6216325B2 (en) | 2011-11-23 | 2017-10-18 | ノバルティス アーゲー | Pharmaceutical formulation |
| WO2014003677A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2626579A1 (en) * | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
| KR20090094815A (en) * | 2006-11-09 | 2009-09-08 | 애보트 게엠베하 운트 콤파니 카게 | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-17 RU RU2010119929/15A patent/RU2010119929A/en not_active Application Discontinuation
- 2008-10-17 BR BRPI0818340 patent/BRPI0818340A2/en not_active IP Right Cessation
- 2008-10-17 JP JP2010529408A patent/JP2011500649A/en active Pending
- 2008-10-17 CA CA2699301A patent/CA2699301A1/en not_active Abandoned
- 2008-10-17 WO PCT/EP2008/064076 patent/WO2009050291A2/en active Application Filing
- 2008-10-17 CN CN200880112150A patent/CN101827584A/en active Pending
- 2008-10-17 UA UAA201006029A patent/UA100865C2/en unknown
- 2008-10-17 MX MX2010004291A patent/MX2010004291A/en not_active Application Discontinuation
- 2008-10-17 AU AU2008313622A patent/AU2008313622A1/en not_active Abandoned
- 2008-10-17 KR KR1020107010979A patent/KR20100087170A/en not_active Application Discontinuation
- 2008-10-17 EP EP08839333A patent/EP2197425A2/en not_active Withdrawn
- 2008-10-17 PA PA20088800101A patent/PA8800101A1/en unknown
-
2010
- 2010-03-24 ZA ZA2010/02095A patent/ZA201002095B/en unknown
- 2010-04-16 DO DO2010000117A patent/DOP2010000117A/en unknown
- 2010-04-16 GT GT201000102A patent/GT201000102A/en unknown
- 2010-04-27 CO CO10049271A patent/CO6270206A2/en not_active Application Discontinuation
- 2010-05-17 EC EC2010010183A patent/ECSP10010183A/en unknown
- 2010-05-19 CR CR11442A patent/CR11442A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GT201000102A (en) | 2012-03-12 |
| ZA201002095B (en) | 2011-11-30 |
| BRPI0818340A2 (en) | 2015-04-22 |
| CA2699301A1 (en) | 2009-04-23 |
| AU2008313622A1 (en) | 2009-04-23 |
| KR20100087170A (en) | 2010-08-03 |
| DOP2010000117A (en) | 2010-05-15 |
| EP2197425A2 (en) | 2010-06-23 |
| CN101827584A (en) | 2010-09-08 |
| ECSP10010183A (en) | 2010-06-29 |
| WO2009050291A2 (en) | 2009-04-23 |
| UA100865C2 (en) | 2013-02-11 |
| RU2010119929A (en) | 2011-11-27 |
| PA8800101A1 (en) | 2009-05-15 |
| MX2010004291A (en) | 2010-08-02 |
| CR11442A (en) | 2010-09-06 |
| WO2009050291A3 (en) | 2010-04-08 |
| JP2011500649A (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270206A2 (en) | SOLID DISPERSION PRODUCT OF DRUGS BASED ON N-ARIL UREA | |
| DOP2010000114A (en) | SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND | |
| Kurakula et al. | Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition | |
| US10632074B2 (en) | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product | |
| AR001458A1 (en) | Pharmaceutical composition for transdermal administration. | |
| PE20071139A1 (en) | SUSTAINED RELEASE FORMULATION INCLUDING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS | |
| AR077411A2 (en) | SOLID PHARMACEUTICAL DOSAGE FORM, WITH LOPINAVIR AND RITONAVIR, AND PROCESS FOR PREPARATION. | |
| RU2004137118A (en) | PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND METHOD OF ITS PRODUCTION | |
| CR9704A (en) | PHARMACEUTICAL COMPOSITION OF MODIFIED LIBERATION, PREPARATION PROCESS AND METHOD TO USE THE SAME. | |
| EP4218724A3 (en) | Microstructure array for delivery of active agents | |
| WO2010015567A3 (en) | Controlled release formulations using intelligent polymers | |
| ES2183602T3 (en) | MICROENCAPSULATED FORMULATIONS. | |
| AR054238A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A BIGUANIDA AND A DERIVATIVE OF TIAZOLIDINDIONA | |
| JP2017528434A (en) | Microneedle containing retinol or retinol derivative | |
| AR080736A1 (en) | PHARMACEUTICAL COMPOSITION OF RAPID DISSOLUTION, USEFULLY DIVERSE, AND PROCESS TO PREPARE IT | |
| Anjani et al. | Soluplus®-based dissolving microarray patches loaded with colchicine: Towards a minimally invasive treatment and management of gout | |
| RU2488384C2 (en) | Compositions for treating neoplastic diseases | |
| JP2010536837A5 (en) | ||
| AR061830A1 (en) | HIGHLY EFFICIENT LIQUID FORMULATION OF PIRETROIDS | |
| PA8615501A1 (en) | PHARMACEUTICAL FORMULATIONS TRANSDERMICAS | |
| UA83036C2 (en) | Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances | |
| AR048432A1 (en) | DIURETIC COMPOSITIONS OF PROLONGED RELEASE | |
| PE20110923A1 (en) | PRE-COMPACTED RAPID DISINTEGRATION FORMULATIONS OF COMPOUNDS WITH LOW ORAL BIODAVAILABILITY | |
| AR078167A1 (en) | SOLID DISPERSION UNDERSTANDING AN ANTI-HIV AGENT | |
| CO6270249A2 (en) | FIBER, FILM OR FOAM THAT INCLUDES A PLASTIFIER AND A GEL LINKED TO LOADED CLAY AND METHODS FOR ITS PRODUCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |